Related Experiment Videos
Myocardial scintigraphy with I-123 heptadecanoic acid as a test for coronary heart disease
European Journal of Nuclear Medicine
|January 1, 1987
Insights
123I-heptadecanoic acid myocardial scintigraphy shows limited use for diagnosing coronary heart disease. The test lacks the necessary sensitivity and specificity for widespread clinical application in patients with suspected heart disease.
Area of Science:
- Cardiology
- Nuclear Medicine
- Diagnostic Imaging
Background:
- Coronary heart disease (CHD) diagnosis relies on accurate imaging.
- Myocardial scintigraphy is an established diagnostic tool.
Purpose of the Study:
- To evaluate 123I-heptadecanoic acid (123I-HDA) for myocardial scintigraphy.
- To assess its diagnostic utility in coronary heart disease.
Main Methods:
- Compared 123I-HDA scintigraphy results.
- Evaluated subjects with high and low pre-test probabilities of CHD.
Main Results:
- The test identified some patients with high probability of CHD.
- Sensitivity and specificity were insufficient for routine use.
Conclusions:
- 123I-HDA myocardial scintigraphy is not suitable for routine CHD diagnosis.
- Further research may be needed to improve its clinical utility.
Abstract:
We have evaluated 123I-heptadecanoic acid for myocardial scintigraphy in the diagnosis of coronary heart disease by comparing the results obtained with it in subject groups with high and low probabilities of disease. We conclude that although some patients in the former group can be identified, the test is neither sufficiently sensitive nor specific for routine clinical use.